Recent research have focused on the convergence of glucagon-like peptide-1|GIP|glucagon receptor stimulant therapies and DA communication. While GLP agonists are increasingly employed for managing type 2 diabetes mellitus, their unexpected impacts on motivation circuits, specifically governed by dopamine systems, are gaining considerable focus. Thi